Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 55

1.

GRHL1 acts as tumor suppressor in neuroblastoma and is negatively regulated by MYCN and HDAC3.

Fabian J, Lodrini M, Oehme I, Schier MC, Thole TM, Hielscher T, Kopp-Schneider A, Opitz L, Capper D, von Deimling A, Wiegand I, Milde T, Mahlknecht U, Westermann F, Popanda O, Roels F, Hero B, Berthold F, Fischer M, Kulozik AE, Witt O, Deubzer HE.

Cancer Res. 2014 May 1;74(9):2604-16. doi: 10.1158/0008-5472.CAN-13-1904. Epub 2014 Jan 13.

PMID:
24419085
[PubMed - indexed for MEDLINE]
2.

NCYM, a Cis-antisense gene of MYCN, encodes a de novo evolved protein that inhibits GSK3β resulting in the stabilization of MYCN in human neuroblastomas.

Suenaga Y, Islam SM, Alagu J, Kaneko Y, Kato M, Tanaka Y, Kawana H, Hossain S, Matsumoto D, Yamamoto M, Shoji W, Itami M, Shibata T, Nakamura Y, Ohira M, Haraguchi S, Takatori A, Nakagawara A.

PLoS Genet. 2014 Jan;10(1):e1003996. doi: 10.1371/journal.pgen.1003996. Epub 2014 Jan 2.

PMID:
24391509
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Genomic markers for neuroblastoma risk estimation: superseding tumor stage, age and MYCN?

Oberthuer A.

Biomark Med. 2013 Dec;7(6):905-8. doi: 10.2217/bmm.13.97. No abstract available.

PMID:
24266822
[PubMed - indexed for MEDLINE]
4.

Involvement of germline DDX1-MYCN duplication in inherited nephroblastoma.

Fievet A, Belaud-Rotureau MA, Dugay F, Abadie C, Henry C, Taque S, Andrieux J, Guyetant S, Robert M, Dubourg C, Edan C, Rioux-Leclercq N, Odent S, Jaillard S.

Eur J Med Genet. 2013 Dec;56(12):643-7. doi: 10.1016/j.ejmg.2013.10.004. Epub 2013 Oct 24.

PMID:
24161495
[PubMed - indexed for MEDLINE]
5.

Neuroblastoma and MYCN.

Huang M, Weiss WA.

Cold Spring Harb Perspect Med. 2013 Oct 1;3(10):a014415. doi: 10.1101/cshperspect.a014415. Review.

PMID:
24086065
[PubMed - indexed for MEDLINE]
6.

A transplantable TH-MYCN transgenic tumor model in C57Bl/6 mice for preclinical immunological studies in neuroblastoma.

Kroesen M, Nierkens S, Ansems M, Wassink M, Orentas RJ, Boon L, den Brok MH, Hoogerbrugge PM, Adema GJ.

Int J Cancer. 2014 Mar 15;134(6):1335-45. doi: 10.1002/ijc.28463. Epub 2013 Sep 14.

PMID:
24038106
[PubMed - indexed for MEDLINE]
7.

Constitutional 11q14-q22 chromosome deletion syndrome in a child with neuroblastoma MYCN single copy.

Passariello A, De Brasi D, Defferrari R, Genesio R, Tufano M, Mazzocco K, Capasso M, Migliorati R, Martinsson T, Siani P, Nitsch L, Tonini GP.

Eur J Med Genet. 2013 Nov;56(11):626-34. doi: 10.1016/j.ejmg.2013.08.005. Epub 2013 Sep 13.

PMID:
24035971
[PubMed - indexed for MEDLINE]
8.

Detection of MYCN amplification using blood plasma: noninvasive therapy evaluation and prediction of prognosis in neuroblastoma.

Kojima M, Hiyama E, Fukuba I, Yamaoka E, Ueda Y, Onitake Y, Kurihara S, Sueda T.

Pediatr Surg Int. 2013 Nov;29(11):1139-45.

PMID:
24022278
[PubMed - indexed for MEDLINE]
9.

Dihydropyrimidinase-like protein 3 expression is negatively regulated by MYCN and associated with clinical outcome in neuroblastoma.

Tan F, Wahdan-Alaswad R, Yan S, Thiele CJ, Li Z.

Cancer Sci. 2013 Dec;104(12):1586-92. doi: 10.1111/cas.12278. Epub 2013 Oct 21.

PMID:
24011394
[PubMed - indexed for MEDLINE]
10.

BET inhibition silences expression of MYCN and BCL2 and induces cytotoxicity in neuroblastoma tumor models.

Wyce A, Ganji G, Smitheman KN, Chung CW, Korenchuk S, Bai Y, Barbash O, Le B, Craggs PD, McCabe MT, Kennedy-Wilson KM, Sanchez LV, Gosmini RL, Parr N, McHugh CF, Dhanak D, Prinjha RK, Auger KR, Tummino PJ.

PLoS One. 2013 Aug 23;8(8):e72967. doi: 10.1371/journal.pone.0072967. eCollection 2013.

PMID:
24009722
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Novel anthranilamide-pyrazolo[1,5-a]pyrimidine conjugates modulate the expression of p53-MYCN associated micro RNAs in neuroblastoma cells and cause cell cycle arrest and apoptosis.

Ramaiah MJ, Pushpavalli SN, Lavanya A, Bhadra K, Haritha V, Patel N, Tamboli JR, Kamal A, Bhadra U, Pal-Bhadra M.

Bioorg Med Chem Lett. 2013 Oct 15;23(20):5699-706. doi: 10.1016/j.bmcl.2013.08.018. Epub 2013 Aug 12.

PMID:
23992861
[PubMed - indexed for MEDLINE]
12.

New strategies in neuroblastoma: Therapeutic targeting of MYCN and ALK.

Barone G, Anderson J, Pearson AD, Petrie K, Chesler L.

Clin Cancer Res. 2013 Nov 1;19(21):5814-21. doi: 10.1158/1078-0432.CCR-13-0680. Epub 2013 Aug 21. Review.

PMID:
23965898
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Treatment of children over the age of one year with unresectable localised neuroblastoma without MYCN amplification: results of the SIOPEN study.

Kohler JA, Rubie H, Castel V, Beiske K, Holmes K, Gambini C, Casale F, Munzer C, Erminio G, Parodi S, Navarro S, Marquez C, Peuchmaur M, Cullinane C, Brock P, Valteau-Couanet D, Garaventa A, Haupt R.

Eur J Cancer. 2013 Nov;49(17):3671-9. doi: 10.1016/j.ejca.2013.07.002. Epub 2013 Jul 29.

PMID:
23907002
[PubMed - indexed for MEDLINE]
14.

Neuroblastoma of undifferentiated subtype, prognostic significance of prominent nucleolar formation, and MYC/MYCN protein expression: a report from the Children's Oncology Group.

Wang LL, Suganuma R, Ikegaki N, Tang X, Naranjo A, McGrady P, London WB, Hogarty MD, Gastier-Foster JM, Look AT, Park JR, Maris JM, Cohn SL, Seeger RC, Shimada H.

Cancer. 2013 Oct 15;119(20):3718-26. doi: 10.1002/cncr.28251. Epub 2013 Jul 30.

PMID:
23901000
[PubMed - indexed for MEDLINE]
15.

RUNX3 interacts with MYCN and facilitates protein degradation in neuroblastoma.

Yu F, Gao W, Yokochi T, Suenaga Y, Ando K, Ohira M, Nakamura Y, Nakagawara A.

Oncogene. 2014 May 15;33(20):2601-9. doi: 10.1038/onc.2013.221. Epub 2013 Jul 15.

PMID:
23851507
[PubMed - indexed for MEDLINE]
16.

G34, another connection between MYCN and a pediatric tumor.

Huang M, Weiss WA.

Cancer Discov. 2013 May;3(5):484-6. doi: 10.1158/2159-8290.CD-13-0126.

PMID:
23658294
[PubMed - indexed for MEDLINE]
17.

MYCN/LIN28B/Let-7/HMGA2 pathway implicated by meta-analysis of GWAS in suppression of post-natal proliferation thereby potentially contributing to aging.

Keane M, de Magalhães JP.

Mech Ageing Dev. 2013 Jul-Aug;134(7-8):346-8. doi: 10.1016/j.mad.2013.04.006. Epub 2013 Apr 29. Review.

PMID:
23639551
[PubMed - indexed for MEDLINE]
18.

High incidence of MYCN amplification in a Moroccan series of neuroblastic tumors: comparison to current biological data.

Tabyaoui I, Tahiri-Jouti N, Serhier Z, El Maani K, Cherkaoui S, Al Zemmouri M, Othmani MB, Zamiati S.

Diagn Mol Pathol. 2013 Jun;22(2):112-8. doi: 10.1097/PDM.0b013e318277448e.

PMID:
23628823
[PubMed - indexed for MEDLINE]
19.

MYCN and HDAC2 cooperate to repress miR-183 signaling in neuroblastoma.

Lodrini M, Oehme I, Schroeder C, Milde T, Schier MC, Kopp-Schneider A, Schulte JH, Fischer M, De Preter K, Pattyn F, Castoldi M, Muckenthaler MU, Kulozik AE, Westermann F, Witt O, Deubzer HE.

Nucleic Acids Res. 2013 Jul;41(12):6018-33. doi: 10.1093/nar/gkt346. Epub 2013 Apr 26.

PMID:
23625969
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Glioblastoma: histone mutations take the MYCN.

McCarthy N.

Nat Rev Cancer. 2013 Jun;13(6):382-3. doi: 10.1038/nrc3527. Epub 2013 Apr 25. No abstract available.

PMID:
23615692
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk